Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Sinovac Biotech Announces Receipt of Delisting Determination Letter from Nasdaq 2017-11-04 04:20
Elucidation of Bone Regeneration Mechanism 2017-11-03 15:35
Opening Ceremony of CStone Pharmaceuticals' Suzhou Translational Medicine Research Center and an associated Immuno-Oncology Forum was Successfully Held in Suzhou 2017-11-03 14:16
WuXi Biologics and Pall Corporation Establish Joint Continuous Bioprocess Laboratory 2017-11-03 10:30
Elucidation of Bone Regeneration Mechanism 2017-11-03 00:00
VolitionRx Limited Schedules Third Quarter 2017 Earnings Conference Call and Business Update 2017-11-02 20:30
China Biologic Reports Unaudited Financial Results for the Third Quarter of 2017 2017-11-02 04:30
ImmunoMet Appoints Benjamin R. Cowen, PhD, MBA, as Chief Executive Officer 2017-11-01 20:30
TWi Biotechnology Inc. Presents Positive Results from AC-201 CR Phase 2 Proof-of-Concept Study in Gout Patients in 2017 ACR/ARPH Annual Meeting 2017-11-01 17:05
BGI's MGI Tech Launches Two New NGS Platforms 2017-10-31 14:30
China Biologic Products to Report Third Quarter of 2017 Financial Results 2017-10-25 20:00
Medeon Biodesign Announces Successful Clinical Use of AbClose(TM) Laparoscopic Port Site Closure Device in the United States 2017-10-20 15:00
WuXi AppTec Acquires ResearchPoint Global to Better Enable Clinical Development Worldwide 2017-10-18 05:30
China Biologic Products Announces Conference Call to Discuss TianXinFu Acquisition 2017-10-13 20:00
China Biologic Agrees to Acquire TianXinFu from PWM 2017-10-12 20:30
Samsung BioLogics Receives the 1st FDA Approval at the World's Largest Plant 2017-10-12 11:00
China Biologic Receives Approval for Commercial Manufacturing of Human Fibrinogen 2017-10-09 20:30
WuXi AppTec Receives 2017 Global Integrated Drug R&D Services Competitive Strategy Innovation & Leadership Award from Frost & Sullivan 2017-10-09 08:00
ImmunoMet Announces Initiation of Phase 1 Clinical Study of IM156, an OXPHOS Inhibitor, in Patients with Solid Tumors 2017-10-03 20:30
Sinobioway Consortium Provides Update on Acquiring Sinovac Biotech (Nasdaq: SVA) at the Purchase Price of $8 Per Share 2017-09-29 20:00
1 141 142 143 144 145 220